HTB homepage • Conference reports • Articles by subject • Subscribe 13 November 2018 Contents Editorial 13 November 2018: vol 19 no 17: HIVR4P and Glasgow conferences: first reports Conference reports Glasgow HIV Congress (2018) No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester Viral dynamics of dolutegravir-based dual versus triple ART Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV Fostemsavir: 48-week phase 3 results from BRIGHTE study Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon 3rd HIV Research for Prevention Conference (R4P2018) How to evaluate PrEP and vaccines: urgency for next generation compounds Dual bNAb maintains viral suppression for median 21 weeks off-ART Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP 3D imaging show HIV infection might establish within hours bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges Why U=U does not cover breastfeeding Antiretrovirals FDA updates rilpivirine label for use during pregnancy Treatment access Activists demand $1 a day access to bedaquiline for MDR TB Guidelines EACS guidelines – version 9.1 update (2018) Side effects Cannabis-based products for medicinal use: Guidance to clinicians PDFs 13 November 2018: vol 19 no 17 HTB homepage • Conference reports • Articles by subject • Subscribe
